Xavier Pi-Sunyer, MD, MPH describes how physicians can make the decision between whether to prescribe an injectable GLP-1 agonist treatment or an oral DPP-4 inhibitor when seeking to lower A1C levels. Most type 2 diabetes patients begin treatment on Metformin, which may effectively control the disease for a time, but ultimately fails as a long-term solution. GLP-1 agonists and DPP-4 inhibitors can serve as a second line of defense, the former of which is more potent when it comes to lowering A1C.